Verrica Pharmaceuticals (VRCA) Retained Earnings (2017 - 2026)
Verrica Pharmaceuticals (VRCA) posted quarterly Retained Earnings of -$334.6 million for Q1 2026, down 5.63% year-over-year from -$354.5 million in Q1 2025, and down 2.98% quarter-over-quarter from -$324.9 million in Q4 2025.
Verrica Pharmaceuticals (VRCA) Retained Earnings (2017 - 2026) Analysis & Trends
Verrica Pharmaceuticals' Retained Earnings history runs 10 years deep, the most recent figure standing at -$334.6 million for Q1 2026.
- In Q1 2026, Retained Earnings fell 5.63% year-over-year to -$334.6 million; the TTM figure through Mar 2026 stood at -$334.6 million (down 5.63% YoY), while the FY2025 annual figure was -$324.9 million, down 5.83% from the prior year.
- Retained Earnings for Q1 2026 stood at -$334.6 million, down from -$324.9 million in the prior quarter.
- The five-year high for Retained Earnings was -$29000.0 in Q3 2022, with the low at -$334.6 million in Q1 2026.
- The 5-year median for Retained Earnings is -$250.8 million (2024), against an average of -$225.0 million.
- Peak annual rise in Retained Earnings reached 99.98% in 2022, while the deepest fall reached 4913433.33% in 2022.
- Verrica Pharmaceuticals' Retained Earnings stood at -$163.5 million in 2022, then sank by 40.99% to -$230.4 million in 2023, then slumped by 33.23% to -$307.0 million in 2024, then slipped by 5.83% to -$324.9 million in 2025, then dropped by 2.98% to -$334.6 million in 2026.
- Business Quant data shows VRCA's Retained Earnings at -$334.6 million in Q1 2026, -$324.9 million in Q4 2025, and -$316.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 4.38 Bn |
| 10 | Verrica Pharmaceuticals | 102.80 Mn | 91.60 Mn | - | -347.75 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -347.75 Mn |
| Mar 31, 2026 | -334.60 Mn |
| Dec 31, 2025 | -324.91 Mn |
| Sep 30, 2025 | -316.84 Mn |
| Jun 30, 2025 | -316.60 Mn |
| Mar 31, 2025 | -316.77 Mn |
| Dec 31, 2024 | -307.03 Mn |
| Sep 30, 2024 | -290.83 Mn |
| Jun 30, 2024 | -268.00 Mn |
| Mar 31, 2024 | -250.80 Mn |
| Dec 31, 2023 | -230.45 Mn |
| Sep 30, 2023 | -205.83 Mn |
| Jun 30, 2023 | -181.00 Mn |
| Mar 31, 2023 | -170.04 Mn |
| Dec 31, 2022 | -163.45 Mn |
| Sep 30, 2022 | -29,000.00 |
| Jun 30, 2022 | -64,000.00 |
| Mar 31, 2022 | -147.40 Mn |
| Dec 31, 2021 | -138.97 Mn |
| Sep 30, 2021 | -129.43 Mn |